Welcome to our dedicated page for Roivant Sciences news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Roivant Sciences (ROIVW) delivers innovative biopharmaceutical solutions through its subsidiary-driven model, focusing on unmet needs in immunology and dermatology. This news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including clinical trial results, FDA submissions, and subsidiary partnerships. Our curated feed ensures you never miss critical updates about novel antibody therapies, small molecule advancements, or commercial-stage product launches.
Key resources include earnings reports, research collaborations, and pipeline expansion announcements. Bookmark this page for streamlined tracking of Roivant's progress in autoimmune disease treatments and topical therapeutic innovations. Check regularly for authoritative updates directly impacting market positioning and therapeutic development timelines.
Roivant Sciences reported strong early demand for VTAMA, with 14,000 prescriptions in the first 11 weeks post-launch, marking it as the top prescribed topical for psoriasis in the US. The company announced a net loss of $353.8 million for Q1 2022, up from $101.1 million in Q1 2021. R&D expenses increased to $135.8 million, and SG&A expenses rose to $149.1 million, largely due to heightened share-based compensation. The ongoing trials for brepocitinib and tapinarof are progressing well, with data expected in late 2023. Investor day scheduled for September 28 will provide further updates.
Roivant Sciences (Nasdaq: ROIV) announced an investor call and webcast on August 15, 2022, at 8:00 a.m. EDT, to discuss its financial results for Q1 ended June 30, 2022, and provide a corporate update. Additionally, an investor day is scheduled for September 28, 2022, at 11:00 a.m. EDT, to offer updates on Roivant and its subsidiaries, known as Vants. The company aims to improve healthcare delivery and develop transformative medicines more efficiently. The press release serves as a reminder for both events, intended for investor engagement and transparency.
Roivant Sciences has reported significant developments and financial results for the fiscal year ending March 31, 2022. The FDA approved VTAMA (tapinarof) for plaque psoriasis, marking a milestone as the first new chemical entity in 25 years. With $2.1 billion in cash, Roivant prioritizes its pipeline and has initiated a strategic review, discontinuing non-essential programs to focus on high-value opportunities. Research and development expenses increased significantly, amounting to $483 million. Despite challenges, the company remains positioned for growth with ongoing trials and a robust commercial strategy.
Priovant Therapeutics, a collaboration between Roivant Sciences and Pfizer, is focusing on developing brepocitinib, a first-in-class dual inhibitor targeting TYK2 and JAK1. Earlier this quarter, a Phase 3 trial for dermatomyositis (VALOR) was initiated, while a Phase 2b study for systemic lupus erythematosus (SLE) is expected to yield results in the second half of 2023. Brepocitinib has shown statistically significant results in five prior placebo-controlled studies. The need for effective therapies in severe autoimmune diseases underscores the potential of brepocitinib in clinical treatments.
Roivant Sciences (Nasdaq: ROIV) will host a live conference call and webcast on June 28, 2022, at 8:00 a.m. EDT to discuss its financial results for Q4 and the fiscal year ending March 31, 2022. Investors can join the call by dialing +1-844-224-1923 (domestic) or +1-214-989-7105 (international) using conference ID 1036178. A recording of the call will be available on Roivant’s website post-event. The company focuses on improving healthcare delivery and developing transformative medicines.
Dermavant Sciences announced the FDA's approval of VTAMA (tapinarof) cream, a steroid-free topical medication for plaque psoriasis in adults. In the pivotal Phase 3 trials, VTAMA cream showed significant efficacy, with 36%-40% of patients achieving clear skin compared to 6% with a vehicle. The remittive effect lasted approximately four months after treatment cessation. With a favorable safety profile and patient satisfaction rates over 80%, Dermavant aims for a June 2022 product launch. This positions VTAMA as a potential preferred treatment option in a market underserved by recent innovations.
Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences. CEO Matt Gline will present at the UBS Global Healthcare Conference on May 23, while CFO Richard Pulik will join a fireside chat at the H.C. Wainwright Conference on May 24. Gline will also participate in the Jefferies Healthcare Conference on June 8, followed by Pulik and President Mayukh Sukhatme at the Goldman Sachs Conference on June 14. Live webcasts of these events will be available on Roivant's investor website.
Aruvant Sciences presented clinical data on its gene therapy ARU-1801 for severe sickle cell disease (SCD) at the ASGCT annual meeting on May 16, 2022. The data indicates ARU-1801 significantly reduces vaso-occlusive events and hospitalization days for patients. This therapy uniquely employs reduced intensity conditioning, setting it apart from other treatments. In the ongoing MOMENTUM trial, participants showed durable responses with four out of five experiencing complete resolution of severe events. These findings may enhance patient quality of life and lower healthcare costs.
Roivant Sciences has appointed Dr. Srini Ramanathan as Chief Development Officer, bringing over 20 years of drug development experience from Horizon Therapeutics. Dr. Ramanathan has a proven track record in advancing clinical portfolios and has contributed to multiple drug approvals in virology and oncology. Roivant's subsidiaries, Proteovant Therapeutics and VantAI, have also established collaborations with Blueprint Medicines, Janssen, and Boehringer Ingelheim, focusing on innovative drug development with potential aggregate milestone payments exceeding $1 billion.
Dermavant Sciences announced positive results from the Phase 3 PSOARING 3 long-term extension study for tapinarof cream 1% in treating plaque psoriasis. Over 52 weeks, tapinarof showed durable improvements in efficacy, quality of life, and tolerability without irritation. The study demonstrated significant enhancements in key metrics such as % body surface area (%BSA) affected and Psoriasis Area and Severity Index (PASI). Dermavant aims for FDA approval, with a target action date set for Q2 2022, which could position tapinarof as a novel therapeutic option for psoriasis patients.
